NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive shared pivotal updates with Proactive, announcing the company’s engagement of a Clinical Research Organization to conduct a Phase II clinical trial for its innovative broad-spectrum antiviral therapy. This milestone represents a significant step in advancing the therapy through the regulatory process. The upcoming Phase II trial will evaluate the effectiveness of the therapy in treating MPox, a disease caused by the human Mpox virus that has triggered a regional pandemic in parts of Africa, including the Democratic Republic of Congo and Uganda. In 2024, the World Health Organization declared MPox a Public Health Emergency of International Concern. Currently, no approved treatments exist for infections caused by this virus. The therapy has shown strong antiviral activity in preclinical studies, particularly against an orthopoxvirus model that serves as a critical predictor of efficacy for MPox and Smallpox. Notably, its effectiveness matched that of tecovirimat, a widely recognized antiviral, in both direct skin and lung infection models. Dr. Diwan underscored the potential impact of this therapy in addressing a pressing global health challenge, positioning NanoViricides as a leader in developing innovative treatments for diseases caused by orthopoxviruses. With this trial, the company aims to provide a critical solution to an urgent unmet medical need. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc